knowledge -WSS

knowledge

author：leisure time 2025-09-03 03:23:00 - browse：33

ANDREW YATES/AFP via Getty Images

WASHINGTON — A federal judge in Delaware on Friday ruled against AstraZeneca in a case challenging the constitutionality of Medicare’s new drug price negotiation program.

Colm Connolly, chief judge of the U.S. District Court of Delaware, ruled against the company on all its major arguments. He wrote that AstraZeneca had not proved that Medicare’s new drug price negotiation program jeopardizes its constitutional property rights, and that the company didn’t have standing to challenge the guidance Medicare issued to implement the program.

The case is the first of a slew of cases filed by the pharmaceutical industry and its allies to be decided at the district court level. The Delaware ruling is a blow, as several of the other cases made similar arguments about how the program violates drugmakers’ constitutional property rights.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： President Biden's budget: Here's what you might have missed

WSS

Pig kidney works a record two months in donated body

PEPFAR is under serious threat — and so is global health

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Food makers to regulators: Ultra

Regeneron agrees to White House price limits on anti

hotspot

knowledge

focus

How to save PrEP access — and even expand it

Steward Health Care Massachusetts hospitals face fiscal disaster

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

President Biden's budget: Here's what you might have missed

How to save PrEP access — and even expand it

How to save health care price transparency rules

Moonlake's readout produced a cash windfall. Risks remain

Male and female sex labels in research insufficient, scientists say

Moonlake's readout produced a cash windfall. Risks remain

First U.S. drug developed to treat liver disease MASH is approved

knowledge

Male and female sex labels in research insufficient, scientists say

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

RaDonda Vaught links Vanderbilt hospital issues to patient death

Walmart eyes Medicare Advantage provider ChenMed

Steward Health Care Massachusetts hospitals face fiscal disaster

FDA panel endorses Alnylam’s heart drug — after picking it apart

entertainment

focus

explore

focus